海外の治験の状況「前立腺癌」での検索結果
107件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not recruiting
- A randomised trial investigating the effect on biomedical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definite radiation treatment for localised carcinoma of the prostate (RADAR)
- Localised carcinoma of the prostate
- Australia, New Zealand
- 2003-12-23
Not Recruiting
- Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
- Mestatic Hormone Refractory Prostate Cancer
- Argentina, Australia, Austria, Belgium, Canada, Croatia, Czech Republic, Finland, France, Hungary, India, Iran (Islamic Republic of), Israel, Italy, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Taiwan, United Kingdom
- 2011-06-15
Not Recruiting
- Does imatinib therapy lead to an increased uptake of low molecular weight substances into solid tumor metastasis in patients with hormone refractory prostate cancer? - PET_ONKO
- patients with HRPC and bone metastases will be enrolled in the study
- Austria
- 2006-05-03
Not Recruiting
- Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer
- metastatic hormone-refractory prostate cancer MedDRA version: 9.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer
- Austria
- 2007-06-13
Not Recruiting
- Intermittent Treatment with Taxotere and Prednisone in patients with asymptomatic, hormone-refractory prostate cancer: A Multicenter Phase II Trial - TOPAS
- asymptomatic hormone-refractory prostate cancer
- Austria
- 2007-04-25
Not Recruiting
- Open-Label Access Protocol of Denosumab for Subjects with Advanced Cancer
- Bone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate Cancer MedDRA version: 16.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 16.0 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 16.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Chile, Czech Republic, European Union, France, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Panama, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
- 2011-08-10
Not Recruiting
- A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subjects With Metastatic Hormone Refractory prostate Cancer
- Hormone refractory prostate cancer (HRPC) MedDRA version: 9.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer
- Austria, Belgium, Germany, Netherlands, United Kingdom
- 2007-03-16
